Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01321437 · ClinicalTrials.gov registry record · Phase 2
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
A Phase 2 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01321437 is a Phase 2 study that has completed, run by University of California, Irvine. The registered enrollment target is 11 participants.
The verdict
NCT01321437, a Phase 2 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
Interventions
- OTHER laboratory biomarker analysis
- DRUG Axitinib
- PROCEDURE therapeutic conventional surgery
- OTHER pharmacological study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01321437
The ClinicalTrials.gov registry entry for NCT01321437 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01321437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01321437 about?
NCT01321437 is a clinical study titled "Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma". The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
What is the current status of trial NCT01321437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2011-12. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01321437?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Axitinib (DRUG), therapeutic conventional surgery (PROCEDURE), pharmacological study (OTHER).
Who is sponsoring clinical trial NCT01321437?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.